Skip to main content
OpenTrials
Completed

NCT Number: NCT03358147

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Research Site, Birmingham, Alabama, United States

Loading trial locations.

About this study

A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have a documented history of physician-diagnosed asthma
  • Require inhaled asthma maintenance therapy: has been regularly using an ICS/LABA on a stable regimen for at least 4 weeks
  • Documented reversibility to albuterol
  • A pre-bronchodilator FEV1 >40% and <85% of predicted normal value for subjects 18 to 80 years of age or >40% and <90% of predicted for subjects 12 to <18 years of age
  • Demonstrate acceptable spirometry performance
  • Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol
  • Compliance: must be willing to remain at the study center as required per protocol to complete all visit assessments

Exclusion criteria

  • Oral corticosteroid use (any dose) within 4 weeks
  • Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months (including all forms of tobacco, e-cigarettes, and marijuana)
  • Life-threatening asthma as defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)
  • Completed treatment for lower respiratory infection or asthma exacerbation within 4 weeks
  • Hospitalizations for asthma within 3 months
  • Historical or current evidence of a clinically significant disease
  • Cancer not in complete remission for at least 5 years
  • Treatment with investigational study drug (or device) in another clinical study within the last 30 days or 5 half-lives, whichever is longer
  • Previously randomized in any PT001 study

Treatment and study plan

GP MDI 28.8 μg

Drug

GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID

Other names: GP

GP MDI 14.4 μg

Drug

GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID

Other names: GP

GP MDI 7.2 μg

Drug

GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID

Other names: GP

Placebo MDI

Drug

Placebo taken as 2 inhalations BID

Other names: Placebo

Spiriva Respimat 2.5 μg

Drug

Spiriva Respimat 2.5 μg QD (open-label)

Other names: Spiriva Respimat

Primary outcomes

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4)

    Time frame: Week 24

    Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 4 hours (AUC0-4)AUC was normalized for length of follow up (e.g. typically 4 hours).

Secondary outcomes

  1. Change From Baseline in Morning Pre-dose Trough FEV1

    Time frame: Week 24

  2. Rate of Moderate to Severe Asthma Exacerbations

    Time frame: over 24 Weeks (timepoints of 4, 12 & 20 weeks)

    Rate of moderate to severe Asthma exacerbations (A deterioration of asthma requiring a new or increased dose of ICS for at least 3 days) or severe Asthma exacerbation (Use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days OR a hospitalization or ER visit because of asthma)

  3. Change From Baseline in ACQ-7 (Asthma Control Questionnaire)

    Time frame: Week 24

    ACQ-7: The ACQ, comprising 7 questions, is completed in the clinic and requires subjects to recall their experiences during the previous week (7 days) prior to the study visit. The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze); the ACQ-6 is these symptom measurements plus daily rescue medication use as recalled by the subject; and the ACQ 7 is the ACQ 6 plus airway caliber as measured by pre-bronchodilator FEV1 percent predicted. Each question is scored on a 7-point scale (generally, 0=no impairment, 6=maximum impairment), the questions are equally weighted, and the ACQ score is the mean of the item responses and therefore ranges from 0 (totally controlled) to 6 (severely uncontrolled.

  4. Change From Baseline in ACQ-5 (Asthma Control Questionnaire)

    Time frame: Week 24

    ACQ-5:The ACQ-5 measures 5 symptoms (woken at night by symptoms, wake in the morning with symptoms, limitation of daily activities, shortness of breath, and wheeze). Each question is scored on a 7-point scale (generally, 0=no impairment, 6=maximum impairment), the questions are equally weighted, and the ACQ score is the mean of the item responses and therefore ranges from 0 (totally controlled) to 6 (severely uncontrolled).

  5. Change From Baseline in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ +12)

    Time frame: Week 24

    AQLQ +12 - Asthma Quality of Life Questionnaire The AQLQ +12 is a 32-item validated subject-administered questionnaire that was developed to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (≥18 years of age) and adolescents (12 to 17 years of age) with asthma. The 32 questions in the AQLQ +12 are in 4 domains (symptoms, activity limitation, emotional function, and environmental stimuli). All 4 domains contain standard specific questions relating to each domain. Subjects are asked to think about how they have been during the previous 2 weeks. Responses to each of the 32 questions are on a 7-point scale (7=no impairment to 1=severe impairment). The overall AQLQ +12 score is the mean of all 32 responses. Overall scores range from 1=severe impairment to 7=no impairment.

Sponsors and collaborators

Lead sponsor

Pearl Therapeutics, Inc.

Industry

Registry information

Official study title

A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Nov 30, 2017
Registry last updated
Aug 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.